Risedronate has no adverse effects on mouse haematopoiesis
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
17706020
PII: file/6130/fb2007a0021.pdf
Knihovny.cz E-resources
- MeSH
- Bone Marrow Cells cytology drug effects MeSH
- Phosphates blood MeSH
- Hematopoiesis drug effects MeSH
- Bone Density Conservation Agents adverse effects pharmacology MeSH
- Etidronic Acid adverse effects analogs & derivatives pharmacology MeSH
- Risedronic Acid MeSH
- Leukocytes drug effects MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Seminal Vesicles drug effects MeSH
- Bone Marrow Transplantation MeSH
- Calcium blood MeSH
- Organ Size drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Phosphates MeSH
- Bone Density Conservation Agents MeSH
- Etidronic Acid MeSH
- Risedronic Acid MeSH
- Calcium MeSH
Bisphosphonates are commonly used for treatment of osteoporosis. They inhibit osteoclast activity and thus bone resorption. It was shown that they also affect some other cell types including tumour and endothelial cells. The effects of risedronate on bone marrow microenvironment were not studied yet. As endothelial cells are integral part of bone marrow microenvironment, it is important to know whether prolonged administration of bisphosphonates does not affect haematopoietic stem cells and bone marrow haematopoiesis. We fed mice two weeks with risedronate. We found no effect of risedronate treatment on bone marrow stem cells using the method of congenic bone marrow repopulation. Risedronate administration in the dose which is considered to be comparable to a dose of risedronate used for treatment of osteoporosis in women seems to be safe in terms of effects on mouse haematopoiesis.
